LOGIN

International Epidemiology Databases to Evaluate AIDS

Home >> Publications >> Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.

Publication

Author(s):

Wandeler G, Gerber F, Rohr J, Chi BH, Orrell C, Chimbetete C, Prozesky H, Boulle A, Hoffmann CJ, Gsponer T, Fox MP, Zwahlen M, Egger M, Africa IS.

Pub Title:

Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.

Pub Date:

Dec 3 2013

Pub Region(s):

Southern Africa

Page Number:
521-5

Journal:

Title: 
Antiviral Therapy
Link: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043936/

PubMed: 24296645
Pub PDF: PDF icon nihms-539668.pdf

Abstract
BACKGROUND:
There is debate over using tenofovir or zidovudine alongside lamivudine in second-line antiretroviral therapy (ART) following stavudine failure. We analyzed outcomes in cohorts from South Africa, Zambia and Zimbabwe METHODS: Patients aged ≥16 years who switched from a first-line regimen including stavudine to a ritonavir-boosted lopinavir-based second-line regimen with lamivudine or emtricitabine and zidovudine or tenofovir in seven ART programs in southern Africa were included. We estimated the causal effect of receiving tenofovir or zidovudine on mortality and virological failure using Cox proportional hazards marginal structural models. Its parameters were estimated using inverse probability of treatment weights. Baseline characteristics were age, sex, calendar year and country. CD4 cell count, creatinine and hemoglobin levels were included as time-dependent confounders.

RESULTS: 1,256 patients on second-line ART, including 958 on tenofovir, were analyzed. Patients on tenofovir were more likely to have switched to second-line ART in recent years, spent more time on first-line ART (33 vs. 24 months) and had lower CD4 cell counts (172 vs. 341 cells/μl) at initiation of second-line ART. The adjusted hazard ratio comparing tenofovir with zidovudine was 1.00 (95% confidence interval 0.59-1.68) for virologic failure and 1.40 (0.57-3.41) for death.

CONCLUSIONS: We did not find any difference in treatment outcomes between patients on tenofovir or zidovudine; however, the precision of our estimates was limited. There is an urgent need for randomized trials to inform second-line ART strategies in resource-limited settings.

 

The following websites provide guidelines and policies when citing from PubMed®: http://www.ncbi.nlm.nih.gov/books/NBK7243/
http://www.nlm.nih.gov/bsd/policy/cit_format.html

Citation:

Wandeler G, Gerber F, Rohr J, Chi BH, Orrell C, Chimbetete C, Prozesky H, Boulle A, Hoffmann CJ, Gsponer T, Fox MP, Zwahlen M, Egger M, Africa IS. Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa. Antivir Ther. 2013 Dec 3. doi: 10.3851/IMP2710. [Epub ahead of print] PubMed PMID: 24296645.